Who is sponsoring NCT02606682?

NCT02606682 is sponsored by Neuropore Therapies Inc..

What condition does NCT02606682 study?

NCT02606682 studies Healthy Volunteers.

What drugs are being tested in NCT02606682?

Interventions: NPT200-11, Placebo.

What is the status of NCT02606682?

NCT02606682 is currently COMPLETED.

Last reviewed 2016-02-12 · How we verify

A Phase 1, Randomized, Double-Blind, Single Ascending Dose Trial of the Safety, Tolerability and Pharmacokinetics of NPT200-11 in Healthy Subjects

NCT02606682 Phase 1 COMPLETED

The purpose of this study is to determine the safety, tolerability and blood levels of orally administered NPT200-11 in healthy subjects. In addition, the maximally tolerated dose will be determined.

Details

Lead sponsor	Neuropore Therapies Inc.
Phase	Phase 1
Status	COMPLETED
Enrolment	55
Start date	2015-07
Completion	2016-02

Conditions

Healthy Volunteers

Interventions

NPT200-11
Placebo

Primary outcomes

Safety, including adverse events, physical examinations, ECGs, clinical laboratory tests — Screening (28 days prior to dosing) through Day 7
Safety, as determined by the number of participants with adverse events related to treatment, the number of participants with clinically significant changes in blood pressure, heart rate and respiration, the number of participants with abnormal laboratory values, the number of participants with abnormal ECGs.

Countries

United States